10x Genomics Q2 revenue $115.8M (+170% YoY); settles Bio-Rad litigation

10x Genomics, Inc.

2021-Q2 EPS reported -$0.21 revenue$221,663,000

Revenue $115.8M, up 170% YoY and 9% QoQ; net loss narrowed to $11.1M from $40.2M.
Gross margin 96% aided by $14.7M one-time royalty reversal from Bio-Rad settlement.
Launched Chromium X platform and began shipping Visium Spatial Gene Expression for FFPE.
Global settlement with Bio-Rad resolves all outstanding litigation; cross-license agreement.
Maintains FY2021 revenue guidance $480M-$500M, representing 61%-67% growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.